Related Experiment Videos
[Radiotherapy for stage B prostate cancer]
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology
|September 1, 1992
Summary
Radiotherapy combined with hormone therapy significantly improved outcomes for stage B prostate cancer patients, showing higher atrophy and 5-year non-relapse rates compared to radiotherapy alone.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Context:
- Stage B prostate cancer treatment from 1965-1989.
- Retrospective analysis of 35 patients.
- Utilized radiotherapy alone or combined with hormone therapy.
Purpose:
- Evaluate the efficacy of radiotherapy alone versus combined hormone and radiotherapy for stage B prostate cancer.
- Assess treatment outcomes including lesion improvement, atrophy, and relapse rates.
Summary:
- Radiotherapy alone achieved 95% improvement and 62% atrophy rates.
- Combined therapy yielded 100% improvement and 92% atrophy rates.
- Five-year non-relapse rates were 85% for radiotherapy alone and 100% for combined therapy. All relapses occurred in the atrophy group.
Impact:
- Combined hormone and radiotherapy demonstrates superior outcomes for stage B prostate cancer.
- Atrophy of the primary lesion is a significant indicator for predicting relapse.
- Findings support the use of combined modality treatment for improved patient survival and disease control.